NanoViricides Inc. (NNVC)

[changes_iv]

Infectobesity From Wikipedia, the free encyclopedia

The term "infectobesity" refers to obesity of infectious origin and the emerging field of medical research that studies the relationship between pathogens (disease-causing organisms, such as viruses and bacteria) and weight gain. The term was coined in 2001 by Dr. Nikhil V. Dhurandhar, at the Pennington Biomedical Research Center. (Dhurandhar, 2001).

Bacteria

The study of the effect of infectious agents on metabolism is still in its early stages. Gut flora has been shown to differ between lean and obese humans. There is an indication that gut flora in obese and lean individuals can affect the metabolic potential. This apparent alteration of the metabolic potential is believed to confer a greater capacity to harvest energy contributing to obesity. Whether these differences are the direct cause or the result of obesity has yet to be determined unequivocally.

Viruses

An association between viruses and obesity has been found in humans as well as a number of different animal species. The amount that these associations may have contributed to the rising rate of obesity is yet to be determined.

The fat virus is the popular name for the concept that some obesity in humans and other animals has a viral source. The AD-36 adenovirus has been observed to increase the amount of body fat on laboratory animals, an effect that has been duplicated on chickens and monkeys.

Ad-36 is known to cause obesity in chickens, mice, rats, and monkeys and was present in 30% of obese humans and 11% of nonobese humans. The prevalence of Ad-36 positivity in lean individuals increased from 7% in 1992-1998 to 15-20% in 2002-2009, which paralleled the increase in obesity prevalence.

NanoViricides, Inc. is on-track to the clinical trials 2014, and with its transformational-technology it will make the nation's, the world's, healthcare less expensive and more effective. We need affordable healthcare, out of the hospital healthcare, and NanoViricides, Inc. is a company that is making the case with scientific breakthrough-technology, independent from the immune system, fast-acting and life-saving medicine! To me it is a forgone conclusion. We will be fast-tracked to market, IMHO.

I am just anticipating, speculating that for the FDA doctors, NanoViricides, Inc. bio-nanotechnological FluCide will be a therapeutic drug to assess in terms of toxicity to humans and then give it green-light to prove efficacy...at the marketplace, again IMHO.